Tag Archives: Featured

  Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a company engaged in haematology and in the area of ​​neurodegenerative diseases, have announced that they have signed an important agreement, in which Chiesi has acquired worldwide rights for Deferiprone, an iron chelator indicated for the treatment of ...

Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months! If you would also like to receive our news directly into your inbox, along with thousands of people across the world, subscribe here!

This is the story of the late Mrs. Mary Manachi from New Jersey, USA, who lost 3 children from thalassaemia back in the 50’s-60’s, when no drugs and medical treatments were available to help prevent their death at a fairly young age. Mrs. Manachi passed away a few years ago, ...

  Bluebird bio, Inc. announced earlier today the launch  of ZYNTEGLO™ in Germany,  the company’s one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related ...

The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency‘ (EMA) committee responsible for human medicines, has recently adopted a positive opinion recommending the granting of a marketing authorisation for the medicinal product Deferasirox Accord, by Accord Healthcare S.L.U.   Deferasirox Accord is a generic of Exjade, ...

  Global Blood Therapeutics, Inc. announced only a few hours ago that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (previously known as Voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral ...

Written by Dinar Faiza (edited)   The Indonesian Thalassemia Foundation of Banyumas and the Banyumas District Government organised and launched, from November 1 to November 30, 2019, a massive pilot project of Thalassaemia Prevention Movement 2019, called ”Thalassaemia Month of Banyumas”. Its theme was entitled “Banyumas Goes To Zero Growth ...

  The Emirates Thalassemia Society (ETS), a prominent TIF’s Member, in collaboration with the United Arab Emirates’ Ministry of Education, is organising the 12th Season of  the ”What is Thalassemia?” Competition. The competition has been running successfully in all the schools, universities and colleges across UAE since 2007. It has ...

Global Blood Therapeutics (GBT) and Syros Pharma announced yesterday their partnership to discover, develop and commercialize novel therapies for SickleCell Disease (SCD) and β-thalassaemia.  Under the agreement, Syros will use its leading gene control platform to identify therapeutic targets and discover drugs that induce fetal hemoglobin, and GBT will receive ...

  In light of the rapid scientific developments in the field of thalassaemia and Sickle Cell Disease (SCD) – new drugs and gene therapies – which promise to change the course of these diseases, and given the leading global role of the Thalassaemia International Federation (TIF) since 1986 in informing ...